<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01672645</url>
  </required_header>
  <id_info>
    <org_study_id>B3771001</org_study_id>
    <nct_id>NCT01672645</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.</brief_title>
  <official_title>A Phase 1, Randomized, Double Blind, Placebo Controlled Study To Evaluate The Safety, Tolerability, Immunogenicity, And Exploratory Efficacy Of Multiple Ascending Dose Levels Of Pf-05402536 And Pf-06413367 In Healthy Adult Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of multiple doses of
      PF-05402536 and PF-06413367 in healthy adult smokers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of solicited local reactions (erythema, induration, and pain) and severity of the local reactions as self-reported on electronic diaries (e-diaries) for 7 days following vaccination.</measure>
    <time_frame>Within 7 days after dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of solicited systemic events (fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, and new or worsening joint pain) and severity of solicited systemic events as self-reported on e-diaries for 7 days following vaccination.</measure>
    <time_frame>Within 7 days after dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Unsolicited Treatment-Emergent Adverse Events (AEs) by Seriousness and Relationship to Treatment</measure>
    <time_frame>Baseline up to Day 364</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Safety Laboratory Findings by Seriousness and Relationship to Treatment</measure>
    <time_frame>Baseline up to Day 364</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody titers against nicotine.</measure>
    <time_frame>Up to Day 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Avidity of antibodies against nicotine.</measure>
    <time_frame>Up to Day 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day point prevalence of smoking abstinence</measure>
    <time_frame>Up to Day 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-week continuous abstinence rate from smoking</measure>
    <time_frame>Up to Day 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>smoking behavioral measurements (including Minnesota Nicotine Withdrawal Scale, Modified Cigarette Evaluation Questionnaire, and Brief Questionnaire of Smoking Urges)</measure>
    <time_frame>Up to Day 364</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Smoking</condition>
  <condition>Vaccines</condition>
  <arm_group>
    <arm_group_label>PF-05402536</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06413367</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular, multiple dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NIC7-001</intervention_name>
    <description>Intramuscular, multiple dose</description>
    <arm_group_label>PF-05402536</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NIC7-003</intervention_name>
    <description>Intramuscular, multiple dose</description>
    <arm_group_label>PF-06413367</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline (0.9% sodium chloride)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current cigarette smokers

          -  Males or females of non-child bearing potential, who are between the minimum legal age
             for smoking (approximately 18 or 19 years, depending on local jurisdiction) and 55
             years, inclusive, and who are motivated to stop smoking.

          -  Subjects must have smoked an average of at least 10 cigarettes per day during the past
             year and during the month prior to the prescreening assessment for entry, with no
             period of abstinence greater than 3 months in the past year.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, or neurologic disease that may
             compromise their ability to safely participate in the study.

          -  Active suicidal ideation or history of suicidal behaviors within the past 5 years
             prior to the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INC Research Toronto Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5V 2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Research Montreal, Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2Y 1S1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Research Sherbrooke Inc.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3771001&amp;StudyName=A%20study%20to%20assess%20the%20safety%20and%20tolerability%20of%20different%20doses%20of%20PF-05402536%20and%20PF-06413367%20in%20healthy%20adult%20smokers.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2012</study_first_submitted>
  <study_first_submitted_qc>August 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2012</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking cessation</keyword>
  <keyword>vaccine</keyword>
  <keyword>Phase 1</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

